News Scan for Apr 11, 2018

Monkeypox in Liberia
;
HHS patient transport exercise
;
Universal flu vaccine trial
;
Yellow fever vaccine campaign

Monkeypox confirmed in Liberia

Yesterday Liberian health officials warned of a monkeypox outbreak in the southern county of River Cess, according to China's state news service, Xinhua.

So far, officials have confirmed four cases of the smallpox-like virus, which is not typically deadly but can last several weeks. Officials are also monitoring some suspected cases. The incubation period for monkeypox can be up to 10 days, with lesions lasting 2 to 5 weeks.

Last year, Nigeria had Africa's largest recorded monkeypox outbreak, with 61 confirmed and 172 suspected cases

Monkeypox is most likely transmitted through the consumption or handling of contaminated bushmeat, a common practice in western and central Africa.
Apr 10 Xinhua
story  

 

HHS spearheads largest exercise for moving highly infectious patients

The US Department of Health and Human Services (HHS) said yesterday that it began the largest ever exercise to test the nation's ability to safely and securely move patients who have highly infectious diseases to regional treatment centers.

More than 50 organizations are participating in the exercise, which is coordinated by the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). They include the State Department, the Department of Transportation, regional Ebola treatment centers, local and state health and emergency management agencies, hospitals, airports, and nongovernmental organizations.

Robert Kadlec, MD, who leads ASPR, said, "Saving lives during crises requires preparation and training." He said a tremendous amount of skill and synchronization are needed to move highly infectious patients in a way that protects patients and healthcare workers. "This type of exercise helps ensure that everyone involved is ready for that level of complexity."

The exercise involves moving seven people acting as Ebola patients in different regions of the country. The patients, one of whom is a child, present at one of five medical centers, where healthcare workers collect and ship samples and practice running lab tests. Medical teams will also practice isolating patients and using personal protective equipment (PPE). Then six patients, placed in mobile biocontainment units, will be flown to the regional treatment centers, and the pediatric patient will be transported by ground ambulance.

On arrival, local emergency responders will take patients from the airport to treatment centers by ground ambulances. The exercise runs through tomorrow, and participants will gather on Apr 13 to assess the exercise, compare experiences, and share best practices for moving patients with highly infectious diseases.
Apr 10 HHS press release

 

BiondVax launches US phase 2 trial of universal flu vaccine

BiondVax, a pharmaceutical company based in Israel, today announced that it began enrolling patients in the United States for a phase 2 clinical trial of its universal flu vaccine candidate, M-001.

In a press release, the company said the trial is sponsored by the National Institute of Allergy and Infectious Diseases and is being conducted under a Food and Drug Administration Investigational New Drug application. The vaccine was initially developed at the Weizmann Institute of Science in Israel. It contains nine epitopes common to influenza A and B viruses. Earlier phase 1/2 and phase 2 trials in Israel and Europe suggested that the vaccine was safe, well-tolerated, and immunogenic across a range of flu strains.

The US trial will enroll 120 participants ages 18 to 49 years at three sites. The volunteers will receive either two doses of M-001 or two doses of placebo, with doses spaced several weeks apart. Researchers will compare the safety and immunogenicity of M-001 and placebo. A few months after the second dose, all participants will receive the current unadjuvanted quadrivalent seasonal flu vaccine.

In March, BiondVax announced that it plans to launch a phase 3 trial of the vaccine later this year in Europe.
Apr 11 BiondVax press release

 

WHO to vaccinate nearly 1 billion Africans against yellow fever

The World Health Organization (WHO) announced yesterday plans to vaccinate almost 1 billion African people against yellow fever by 2026. The WHO is partnering with GAVI, the Vaccine Alliance, UNICEF, and 50 other health partners to target 27 African countries at high risk for yellow fever transmission.

"This comprehensive, global strategy offers an unprecedented opportunity to end the devastating Yellow fever epidemics that periodically impact Africa," said Seth Berkley, MD, CEO of Gavi, in a WHO press statement. "Ensuring that the most vulnerable communities have access to the vaccine through routine systems plays a central role in making this happen."

The WHO made the announcement at a regional meeting in Abuja, Nigeria, where it launched the Eliminate Yellow fever Epidemics (EYE) in Africa strategy, the largest vaccination program of its kind. EYE will uses preventive mass vaccination campaigns as well as routine immunizations to target populations across the continent.

In 2016, Angola and the Democratic Republic of the Congo saw re-emergence of yellow fever in large outbreaks that took 400 lives.
Apr 10 WHO statement 

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by

  Become an underwriter»